What is the primary indication for screening a 27-year-old woman for a hypercoagulability condition, given her family history of deep vein thrombosis (DVT) and pulmonary embolism (PE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The correct answer is C. family history. This patient should be counseled that screening for a hypercoagulability condition is recommended due to her family history of thrombotic events. The patient's mother and aunt both have a history of deep vein thrombosis and pulmonary embolism, which suggests a possible hereditary thrombophilia. When multiple first-degree relatives have experienced thrombotic events, especially at relatively young ages (mid-40s), this significantly increases the likelihood of an underlying genetic hypercoagulable disorder such as Factor V Leiden, Protein C or S deficiency, or antithrombin deficiency, as suggested by the American College of Medical Genetics consensus statement on factor V Leiden mutation testing 1.

Key points to consider in this patient's case include:

  • Her desire for pregnancy, as pregnancy itself is a hypercoagulable state that increases thrombosis risk
  • Her current use of oral contraceptives, which is an acquired risk factor that compounds any underlying genetic predisposition to clotting
  • Her smoking history, which also increases the risk of thrombotic events, particularly in young female smokers, as noted in the guidelines 1
  • The importance of identifying a hypercoagulable condition before pregnancy to allow for appropriate prophylactic measures during pregnancy and the postpartum period, when thrombosis risk is highest.

Given these considerations, screening for a hypercoagulability condition is crucial for this patient, primarily due to her family history of thrombotic events, and the potential for an underlying genetic disorder that could significantly impact her health and the health of her future pregnancy.

From the Research

Hypercoagulability Condition Screening

The patient should be counseled that screening for a hypercoagulability condition is recommended due to her:

  • Family history of deep vein thrombosis and pulmonary embolism, as stated in the patient's history 2, 3, 4, 5 Specifically, the patient's family history of thrombotic disorders, including her mother and aunt having a history of deep vein thrombosis and pulmonary embolism, suggests a possible inherited thrombophilia, such as factor V Leiden or the prothrombin gene mutation 2, 3, 4, 5.

Relevant Factors

The following factors are relevant to the patient's condition:

  • Family history: The patient's family history of thrombotic disorders is a significant risk factor for hypercoagulability 2, 3, 4, 5
  • Desire to be pregnant: Pregnancy is a hypercoagulable state, and women with a history of thrombophilia are at increased risk for venous thromboembolism during pregnancy 2, 3, 6
  • Other factors: While the patient's cigarette use, marijuana use, and oral contraceptive use may contribute to her overall health risks, they are not directly related to the recommendation for screening for a hypercoagulability condition 2, 3, 4, 5, 6

Screening Recommendations

Based on the patient's family history and desire to be pregnant, screening for a hypercoagulability condition is recommended to assess her risk for venous thromboembolism and to guide management during pregnancy 2, 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Laboratory thrombophilias and venous thromboembolism.

Vascular medicine (London, England), 2002

Research

Factor V Leiden thrombophilia.

Genetics in medicine : official journal of the American College of Medical Genetics, 2011

Research

Genetics of Hypercoagulable and Hypocoagulable States.

Neurosurgery clinics of North America, 2018

Research

Hypercoagulability: clinical assessment and treatment.

Southern medical journal, 2001

Related Questions

Is Lovenox (enoxaparin) an acceptable treatment for a patient with factor V Leiden mutation and antiphospholipid antibodies?
What are the recommendations for alcohol and smoking in patients with factor V Leiden (factor five Leiden) thrombophilia?
What are the anticoagulation recommendations for a morbidly obese female with factor V Leiden and a history of saddle pulmonary embolism, who is also diabetic and noncompliant?
What is the recommended anticoagulation therapy for a 76-year-old male with a history of Factor V Leiden deficiency and a previous Deep Vein Thrombosis (DVT) with a positive DVT on ultrasound?
Is it medically appropriate to test a 19-year-old male with Factor V Leiden deficiency for the prothrombin gene mutation, given his family history of the mutation?
What is the most likely diagnosis for a 47-year-old woman with morning stiffness, swelling, and tenderness in the metacarpophalangeal and proximal interphalangeal joints, with nodules on the extensor surfaces of the elbows?
What are the causes of Kaposi's Sarcoma (KS)?
What is the most common impacted foreign object in the esophagus?
What are the guidelines for the duration of Hormone Replacement Therapy (HRT)?
What is the most likely diagnosis for an elderly patient with a history of melanoma, presenting with balance difficulties and neurological issues after a head injury, and a subacute subdural hematoma on brain CT scan?
What are the comparative advantages of adding chemotherapy to Osimertinib (Tagrisso, Azd9291) versus Osimertinib (Tagrisso, Azd9291) monotherapy in terms of outcomes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.